MCC
TRIB

Malaga Cove Capital’s Trinity Biotech TRIB Stock Holding History

Malaga Cove Capital’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,140
Closed -$31K – 160
2017
Q3 		$31K Buy
+1,140
New +$31.8K 0.02% 157

Other funds holding TRIB

PIM
Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
LAM
Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
SCM
Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return

Malaga Cove Capital's TRIB Position: Q4 2017 in Review

Malaga Cove Capital sold out of Trinity Biotech (TRIB) in Q4 2017, closing a stake of 1,140 shares — an estimated $31K sold.

Malaga Cove Capital first reported a position in TRIB in Q3 2017 and held it in 1 quarter. The position peaked at $31K in Q3 2017. 48 funds tracked by Wall St. Rank hold TRIB as of Q4 2017.

  • Malaga Cove Capital reported no remaining Trinity Biotech position as of Q4 2017 after selling out during the quarter.
  • Malaga Cove Capital sold 1,140 Trinity Biotech shares in Q4 2017, an estimated $31K.
  • Malaga Cove Capital first reported a position in Trinity Biotech in Q3 2017 and held it in 1 quarter.
  • Malaga Cove Capital's Trinity Biotech position peaked at $31K in Q3 2017.
  • 48 funds tracked by Wall St. Rank held Trinity Biotech as of Q4 2017.

Based on Malaga Cove Capital's 13F filing for Q4 2017, filed 31 Jan 2018.